Accessibility Menu
Idexx Laboratories logo

Idexx Laboratories(NASDAQ) IDXX

Market Cap$43.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+57,668%
5 Year-19%
1 Year-13%
1 Month-2%
$553.31
+1.32%
+7.22Today
After hours$553.52+$0.21 (+0.04%)
Idexx Laboratories last closing stock price
MetricPriceDate
Last closeUSD 553.322026-08-18
Idexx Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.68%USD 586.642026-08-11
1 month-2.49%USD 567.442026-07-17
3 month-0.05%USD 553.582026-05-20
Year to date-18.21%USD 676.532025-12-31
1 year-13.25%USD 637.862025-08-18
3 year+14.39%USD 483.732023-08-18
5 year-18.83%USD 681.712021-08-19
Since inception+57,668.23%USD 0.951991-06-21

Idexx Laboratories Financials at a Glance

Market Cap

$43.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.55B

Net Income (TTM)

$1.14B

EPS (TTM)

$14.23

P/E Ratio

38.89

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$553.31

Volume

570,336.994

Open

$553.73

Previous Close

$553.32

Daily Range

$549.75 - $559.46

52-Week Range

$518.55 - $769.98

Estimated Earnings Date

Nov 2, 2026

IDXX News

An upward trending line graph.

7 Best Industrial ETFs for 2026 and How to Invest

Matt DiLalloAug 11, 2026
Boy holds up globe in green field.

10 Best ESG Investing Stocks for 2026 and How to Invest

Jeremy BowmanJun 17, 2026
GettyImages-1553902230

Got $5,000? Here's the Ultimate Pick-and-Shovel Pet Stock (Spoiler: It's Not Chewy)

Josh Kohn-LindquistFeb 20, 2026
Dog looking at camera with its mouth open

Why Idexx Laboratories Stock Surged by Almost 15% Today

Eric VolkmanNov 3, 2025
GettyImages-1516239450 (1).jpg

Seilern Investment Management Sells $43 Million Worth of IDEXX Laboratories (NASDAQ: IDXX) Stock

Josh Kohn-LindquistOct 14, 2025
investor in business attire reviews information on a tablet

These Were the 5 Top-Performing Stocks in the S&P 500 in August 2025

Jon QuastSep 4, 2025
Foolcom-Featured.png

Idexx (IDXX) Q2 Revenue Jumps 11%

Motley Fool Markets TeamAug 4, 2025
GettyImages-1553902230 (1)

Meet the Little-Known S&P 500 Stock That Has Rocketed 10,230% Higher Since 2000

Josh Kohn-LindquistMar 29, 2025
Page 1

IDXX: Motley Fool Moneyball Superscore

83

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Idexx Laboratories

IDEXX Laboratories, Inc. helps vets treat pets. It makes tests for pet health and water safety. These tools help keep animals and people healthy.

Diagnostics and Digital Tools

  • Companion Animal Diagnostics: Instruments and lab services used by veterinarians; generated $1.1 billion for the three months ended June 30, 2026.
  • Water Quality Products: Tests for microbiological contaminants like E. coli; revenue was $58.6 million for the second quarter of 2026.
  • Livestock and Poultry: Health monitoring for farm animals and dairy safety; earned $35.2 million during the three months ended June 30, 2026.
  • Veterinary Software: Subscription programs for clinic management and digital imaging; recurring revenue was $76.3 million for the quarter ended June 30, 2026.

Growing the Testing Network

  • Placed the IDEXX inVue Dx Analyzer into broad commercial availability during early 2025.
  • Expanded the menu of diagnostic tests to increase volume from existing customers.
  • Increased the installed base of premium instruments by 11% in the first half of 2026.

High Retention and Global Reach

The company uses its own technical and sales teams to support global veterinary practices. This direct connection helps maintain high customer retention and drives recurring sales of testing supplies.

Key Financial Performance Facts

  • Total revenue reached $2.4 billion for the six months ended June 30, 2026, up 11.8% year over year.
  • Gross profit margin increased 140 basis points to 64.0% for the three-month period ended June 30, 2026.
  • Net cash from operating activities was $613.4 million for the six months ended June 30, 2026.
  • Operating income rose 14.1% to $425.6 million during the second quarter of 2026.
  • Net income was $616.9 million for the six-month period ended June 30, 2026.

Bottom Line

IDEXX has evolved from a diagnostic tool maker to a digital health provider for animals. Its broad reach across veterinary clinics and water systems provides steady business growth through recurring sales.

AI Generated • Aug 5, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

11,000

CEO

Michael Erickson, PhD

Website

www.idexx.com

Headquarters

Westbrook, ME 04092, US

IDXX Financials

Key Financial Metrics (TTM)

Gross Margin

62.45%

Operating Margin

32.03%

Net Income Margin

25.03%

Return on Equity

71.96%

Return on Capital

50.70%

Return on Assets

33.11%

Earnings Yield

2.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$43.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.78M

Volume

570.34K

Avg. Volume

656.37K

Financials (TTM)

Gross Profit

$2.84B

Operating Income

$1.46B

EBITDA

$1.62B

Operating Cash Flow

$1.37B

Capital Expenditure

-$117.18M

Free Cash Flow

$1.25B

Cash & ST Invst.

$196.93M

Total Debt

$1.10B

Idexx Laboratories Performance Analysis

Idexx Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,367,324,0004.7%
20232023-12-31USD 3,660,953,0008.7%
20242024-12-31USD 3,897,504,0006.5%
20252025-12-31USD 4,303,702,00010.4%
Idexx Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-0.4%
Q42025-12-31-1.3%
Q12026-03-314.6%
Q22026-06-306.6%
Idexx Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 8.03-6.7%
20232023-12-31USD 10.0625.4%
20242024-12-31USD 10.676.0%
20252025-12-31USD 13.0822.6%
Idexx Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-6.3%
Q42025-12-31-9.4%
Q12026-03-3112.0%
Q22026-06-3021.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.22B

+9.7%

Gross Profit

$779.09M

+12.1%

Gross Margin

64.04%

N/A

Market Cap

$43.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.96M

N/A

Employees

11,000

N/A

Net Income

$338.41M

+15.1%

EBITDA

$468.46M

+14.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$196.93M

+19.6%

Total Debt

$1.10B

-11.4%

Accounts Receivable

$741.67M

+11.8%

Inventory

$391.58M

-0.3%

Long Term Debt

$400.37M

-28.2%

Short Term Debt

$695.71M

+2.3%

Return on Assets

33.11%

N/A

Return on Invested Capital

67.69%

N/A

Free Cash Flow

$322.52M

+112.7%

Operating Cash Flow

$347.16M

+86.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AAgilent Technologies, Inc.
$148.44-0.01%
IQVIQVIA Holdings Inc.
$240.03-0.50%
VEEVVeeva Systems Inc.
$242.75+1.85%
BDXBecton, Dickinson and Company
$180.77-0.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Questions About IDXX

What is the current price of Idexx Laboratories?

Idexx Laboratories is trading at $553.32 per share.

What is the 52-week range for Idexx Laboratories?

Over the past 52 weeks, Idexx Laboratories has traded between $518.55 and $769.98.

How much debt does Idexx Laboratories have?

As of the most recent reporting period, Idexx Laboratories reported total debt of $1.10B.

How much cash does Idexx Laboratories have on hand?

Idexx Laboratories reported $196.93M in cash and cash equivalents in its most recent financial results.

What is Idexx Laboratories’s dividend yield?

Idexx Laboratories does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services